[1].Johnson SR, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024;76(8):1201–1213. doi:10.1002/art.42860.
[2].Maher TM, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2203–2214. doi:10.1056/NEJMoa2503643.
[3].Devaraj A, et al. Baseline Quantitative Computed Tomography Scores Predict Progression in Patients with Progressive Pulmonary Fibrosis. Arthritis Rheumatol. 2026;78(Suppl 9). Abstract 1688.
[4].Oldham JM, et al. Prognostic Potential of Plasma Protein Biomarkers in Patients with Progressive Pulmonary Fibrosis. Arthritis Rheumatol. 2026;78(Suppl 9). Abstract 1633.
[5].Vonk MC, et al. Efficacy and Safety of Nerandomilast in Patients with Autoimmune-Interstitial Lung Disease (ILD) and Progressive Pulmonary Fibrosis in Subgroups by Time Since ILD Diagnosis. Arthritis Rheumatol. 2026;78(Suppl 9). Abstract 1617.
[6].Hoffmann-Vold AM, et al. Effect of Nerandomilast on Survival in Patients with Autoimmune Disease and Progressive Pulmonary Fibrosis (PPF): Number Needed to Treat to Prevent One Death. Late-breaking abstract submitted to ACR Convergence 2026.
[7].Hoffmann-Vold AM, et al. Characterization of Diarrhea Adverse Events with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial. Arthritis Rheumatol. 2026;78(Suppl 9). Abstract 1774.
[8].Hoffmann-Vold AM, et al. Characterization of Weight Loss with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial. Arthritis Rheumatol. 2026;78(Suppl 9). Abstract 1775.